Ovid Therapeutics shares fall 28% as investors question new drug data (OVID)

Markets Insider New York-based biotech company Ovid Therapeutics announced on Monday positive phase 2 trial results for its treatment for a rare disease called Angelman Syndrome. Its stock, however, was down 28% following the announcement. Shares of Ovid Therapeutics fell 28% on Monday, after investors questioned the efficacy of phase 2 data from a new drug used to treat arare disease called Angelman Syndrome. The drug showed a favorable safety profile and was tolerated in adults and adolescents...